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Identity 
Other names: Infantile myofibromatosis; 
Mesenchymal hamartomatosis; Hemangiopericytoma; 
Vascular leiomyoma of the newborn; Congenital 
generalized fibromatosis 
Inheritance: Postulated as autosomal dominant (AD) 
with variable expression or autosomal recessive (AR). 
Clinics 
Myofibromatosis or infantile myofibromatosis (IM) is 
one of the more common fibromatoses that present 
during childhood. Presentation may occur as an adult or 
even prenatally. 
These tumors grow and regress without known 
initiation factors, and the diagnostic classification 
depends solely upon the location of the tumors. 
Individuals with Solitary IM only have tumor 
involvement of the soft tissues. 
However, those individuals with Multiple IM have 
tumors within bone tissue, and those with Generalized 
IM demonstrate visceral tumors. Soft tissue 
involvement may occur in all three, and bone 
involvement may also be present in generalized IM. 
Neoplastic risk 
Risk for neoplasm is considered to be very low. In 
those individuals who have multiple tumors, 
pathogenesis appears to be related to multifocal 
potential, not metastatic potential. 
Treatment 
Treatment is based solely upon clinical presentation.  
Those tumors causing secondary pathology via mass  
 
 
affect are commonly removed. Others may be watched 
due to their potential to regress. 
Evolution 
The evolution of the tumor is not well understood. 
Pathologically, they are well circumscribed. 
Histopathologically, hematoxylin and eosin (H and E) 
staining demonstrates growth in a zonal pattern with 
more primative appearing cells located centrally and 
spindle shaped cells peripherally. The spindle shaped 
cells resemble fibroblasts but are often arranged in a 
pattern similar to fascicles - thus resembling myocytes. 
As some tumors may grow rapidly, it is also common 
to see areas of central necrosis and calcification. 
Prognosis 
Prognosis is usually based upon the secondary 
complications caused by the tumors. Individuals with 
multiple tumors or visceral involvement tend to have 
more complications due to either number the increased 
number or increased possibility of poor location. I 
general, most individuals with uncomplicated 
presentations have a good prognosis. 
Cytogenetics 
Unknown. 
Only two cytogenetic abnormalities in IM tissue have 
been reported: Monosomy 9q/trisomy 16q and an 
interstitial deletion on chromosome 6q. No comparison 
was made with the constitutive karyotype, and direct 
correlation was not able to be confirmed. It is presumed 
that the causative gene might allow for growth potential 
or affect cell cycle to account for the unique properties 
of both growth and regression of these tumors, but as of 
yet no gene has been identified. 
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Hematoxylin and eosin staining of infantile myofibromatosis 
(IM) biopsies. 
A: Family I (III-9), showing zonal pattern of spindle shaped 
cells with central necrosis and calcification. The lesion was 
subcutaneous scalp mass obtained at 4 months of age, and 
the diagnosis of IM was confirmed by outside consultation (Dr. 
C. Coffin, U. of Utah).  
B: Family II (IV-6), shoulder lesion obtained at 3 months of 
age, but present since birth. The sample demonstrates 
prominent vascularity.  
C: Family II (III-5), temporal lesion, biopsed at age 28 years. 
Diagnoses initially considered included fibroblastic 
meningioma, Schwanoma-neurilemmona, and IM. The patient 
has generalized IM confirmed by multiple other biopsies of the 
deltoid, axilla, and shoulders. Note the architectural similarity of 
(B) and (C) despite their different origins. 
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